Nirsevimab for infants born in Galicia
Treatments studied
Part of Infections clinical trials.
This trial tests a preventive medicine called nirsevimab given to infants to see how well it protects them from a common serious lung infection. It is offered as part of regular check-ups for babies born during a specific time period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby was born between April 1, 2023 and March 1, 2026.
- Your baby lives in Galicia, Spain.
- Your baby receives the nirsevimab shot as part of their routine vaccines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well RSV vaccines or antibody shots protect babies from severe respiratory infections. If your baby is under 1 year old, lives in Connecticut, and gets sick with a respiratory infection, they may be able to join.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
This trial studies ways to prevent RSV infections in newborns. If you are a parent who gave birth in France between October 2024 and January 2025, you may be able to help researchers learn how to better protect babies from RSV.
This study tests if the medicine Nirsevimab can help prevent severe RSV (a common winter virus) in infants in Chile. It is for babies born at specific times in 2023–2024, especially those born early or with health problems.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
Hear when a new RSV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.